Inhalational anthrax

This study compares two common antibiotic combinations—vancomycin with piperacillin/tazobactam versus vancomycin with meropenem—to see which is less harmful to the kidneys. About 852 hospitalized adults with serious infections will be randomly assigned to one of the two combos. T…

This study will evaluate how well the drug raxibacumab works and how safe it is for people who have symptoms of inhalational anthrax after a large-scale exposure, such as a bioterrorist attack. Up to 100 people of all ages, including pregnant women and children, who receive the d…

This study will test a medicine called AIGIV for people who have breathed in anthrax germs during a large-scale emergency. The goal is to see if the drug helps more people survive and to check for side effects. The study will only start if a major anthrax event happens, and it wi…

This study will look at 250 people who received the CYFENDUS anthrax vaccine after being exposed to anthrax bacteria during a mass event. Researchers want to see if the vaccine, given along with antibiotics, can prevent inhalational anthrax and anthrax meningitis. The study is ob…

This observational study will look at 10,000 adults in intensive care units (ICUs) around the world during a single 24-hour period. Researchers want to find out how common infections and antibiotic-resistant bacteria are, how they are treated, and how patients recover. No new tre…

This research project aims to understand why older adults get more infections and why those infections can be more serious. By following 23,000 people aged 60 and older, scientists will collect health data and samples like blood and stool to study how the immune system changes wi…

This early-stage study will give a single dose of the experimental antibiotic gepotidacin to 20 hospitalized children aged 2 to 12 who are already receiving standard antibiotics for a bacterial infection or as a preventive measure. Researchers will measure how the drug moves thro…

This study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…

This study will follow 300 adults with severe infections in the ICU to see how levels of specialized pro-resolving mediators (SPMs)—natural molecules that help stop inflammation—change over time. Researchers will use blood samples already collected during routine care, so no extr…